Anika Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
08/08/2024 22:02
* Anika Therapeutics Inc ANIK.OQ reported a quarterly
adjusted
loss of 1 cent per share for the quarter ended in June, higher
than the same quarter last year, when the company reported EPS
of -19 cents. The mean expectation of three analysts for the
quarter was for earnings of 5 cents per share. Wall Street
expected results to range from -1 cents to 16 cents per share.
* Revenue fell 5.4% to $41.92 million from a year ago;
analysts
expected $42.10 million.
* Anika Therapeutics Inc's reported EPS for the quarter was
a loss
of 1 cent.
* The company reported a quarterly loss of $88 thousand.
* Anika Therapeutics Inc shares had risen by 2.4% this
quarter and
gained 14.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Anika
Therapeutics Inc is $32.00
This summary was machine generated from LSEG data August 8 at
09:01 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 0.05 -0.01 Missed
Mar. 31 2024 -0.19 -0.31 Missed
Dec. 31 2023 -0.26 -4.30 Missed
Sep. 30 2023 -0.37 -0.45 Missed